April P, Abeles M, Baraf H, Cohen S, Curran N, Doucette M, Ekholm B, Goldlust B, Knee C M, Lee E
Multicenter Salsalate/Aspirin Comparison Study Group St. Paul, MN.
Semin Arthritis Rheum. 1990 Feb;19(4 Suppl 2):20-8.
In a multicenter, double-blind, parallel-group study, 233 patients with classical or definite RA who demonstrated disease flare during a prestudy washout period were randomized to 12 weeks of treatment with either the nonacetylated salicylate, salsalate (salicylsalicylic acid), or aspirin. Of the 150 patients who completed the study, 83 received salsalate and 67 were treated with aspirin. Doses of the two drugs were calculated to provide equal amounts of bioavailable salicylic acid. The efficacy of salsalate and aspirin, as measured by all the usual variables, was equivalent but aspirin-treated patients had a higher incidence of severe gastrointestinal problems. Thus, this study demonstrated that the acetyl group of aspirin does not enhance the anti-inflammatory efficacy of salicylic acid in RA.
在一项多中心、双盲、平行组研究中，233例在研究前洗脱期出现疾病复发的经典型或确诊类风湿关节炎患者被随机分为两组，分别接受非乙酰化水杨酸盐（双水杨酸酯，即水杨酰水杨酸）或阿司匹林治疗12周。在完成研究的150例患者中，83例接受双水杨酸酯治疗，67例接受阿司匹林治疗。计算两种药物的剂量以提供等量的生物可利用水杨酸。通过所有常用变量衡量，双水杨酸酯和阿司匹林的疗效相当，但接受阿司匹林治疗的患者出现严重胃肠道问题的发生率更高。因此，本研究表明，阿司匹林的乙酰基并未增强水杨酸在类风湿关节炎中的抗炎疗效。
